MapLight Therapeutics Company Insiders
| MPLT Stock | 17.22 0.55 3.10% |
Slightly above 86 percent of MapLight Therapeutics' insiders are activelly selling. The analysis of the overall insider sentiment regarding MapLight Therapeutics Common suggests that a very large number of insiders are panicking. MapLight Therapeutics employs about 114 people. The company is managed by 9 executives with a total tenure of roughly 266 years, averaging almost 29.0 years of service per executive, having 12.67 employees per reported executive.
Insider Sentiment 14
Mostly Selling
Selling | Buying |
Latest Trades
| 2026-02-11 | Robert C Malenka | Disposed 241 @ 18 | View | ||
| 2026-02-10 | Timothy John Garnett | Acquired 14124 @ 17.89 | View | ||
| 2026-02-03 | Robert C Malenka | Disposed 1 @ 18 | View | ||
| 2026-02-02 | Robert C Malenka | Disposed 7039 @ 18.02 | View | ||
| 2026-01-30 | Robert C Malenka | Disposed 6612 @ 18.11 | View | ||
| 2026-01-29 | Robert C Malenka | Disposed 21262 @ 18.55 | View | ||
| 2026-01-28 | Robert C Malenka | Disposed 6524 @ 18.65 | View |
Monitoring MapLight Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MapLight Therapeutics Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. MapLight Therapeutics Workforce Comparison
MapLight Therapeutics Common is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 407. MapLight Therapeutics totals roughly 114 in number of employees claiming about 28% of equities under Health Care industry.
MapLight Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. MapLight Therapeutics Price Series Summation is a cross summation of MapLight Therapeutics price series and its benchmark/peer.
MapLight Therapeutics Notable Stakeholders
A MapLight Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as MapLight Therapeutics often face trade-offs trying to please all of them. MapLight Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting MapLight Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Karoly Nikolich | Founder | Profile | |
| Karl MD | CoFounder Board | Profile | |
| MBA MD | President Founder | Profile | |
| Anatol Kreitzer | Chief Officer | Profile | |
| Erin MD | Chief Officer | Profile | |
| Vishwas Setia | Chief Officer | Profile | |
| Jonathan CPA | Chief Officer | Profile | |
| James Lillie | Chief Officer | Profile | |
| Kristopher JD | General Secretary | Profile |
About MapLight Therapeutics Management Performance
The success or failure of an entity such as MapLight Therapeutics often depends on how effective the management is. MapLight Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of MapLight management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the MapLight management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Capital Employed | (0.62) | (0.65) | |
| Return On Assets | (0.51) | (0.54) | |
| Return On Equity | (0.61) | (0.64) |
Please note, the imprecision that can be found in MapLight Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MapLight Therapeutics Common. Check MapLight Therapeutics' Beneish M Score to see the likelihood of MapLight Therapeutics' management manipulating its earnings.
MapLight Therapeutics Workforce Analysis
Traditionally, organizations such as MapLight Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare MapLight Therapeutics within its industry.MapLight Therapeutics Manpower Efficiency
Return on MapLight Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 |
Additional Tools for MapLight Stock Analysis
When running MapLight Therapeutics' price analysis, check to measure MapLight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MapLight Therapeutics is operating at the current time. Most of MapLight Therapeutics' value examination focuses on studying past and present price action to predict the probability of MapLight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MapLight Therapeutics' price. Additionally, you may evaluate how the addition of MapLight Therapeutics to your portfolios can decrease your overall portfolio volatility.